Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Multiple Dose Study to Assess the Safety and Tolerability of BMS-963272 in Obese But Otherwise Healthy Adults

Phase 1

Completed

Conditions: Obese But Otherwise Healthy Participants

Interventions: Drug: BMS-963272
Drug: Placebo

First Posted Date: 2019-10-04

Last Posted Date: 2020-05-15

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 36

Registration Number: NCT04116632

Locations: 🇺🇸
PRA Health Sciences - Lenexa, Lenexa, Kansas, United States

The Effects Diflunisal on the Levels of BMS-986165 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986165
Drug: diflunisal

First Posted Date: 2019-10-03

Last Posted Date: 2020-08-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 48

Registration Number: NCT04113668

Locations: 🇺🇸
PRA Health Sciences - Lenexa, Lenexa, Kansas, United States

A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: relatlimab
Drug: nivolumab
Drug: rHuPH20

First Posted Date: 2019-10-02

Last Posted Date: 2023-04-06

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 24

Registration Number: NCT04112498

Locations: 🇺🇸
Local Institution - 0001, Hackensack, New Jersey, United States

Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: paclitaxel (PTX)
Biological: nivolumab
Other: nivolumab placebo
Drug: anthracycline
Drug: cyclophosphamide
Drug: Endocrine Therapy
Procedure: Surgery

First Posted Date: 2019-09-30

Last Posted Date: 2025-03-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 521

Registration Number: NCT04109066

Locations: 🇫🇷
Local Institution - 0024, Brest, France
🇫🇷
Local Institution - 0162, Clermont-Ferrand, France
🇫🇷
Local Institution - 0153, Lyon, France

and more 229 locations

A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Biological: Nivolumab
Drug: Prednisone
Other: Placebo
Drug: Docetaxel

First Posted Date: 2019-09-23

Last Posted Date: 2025-06-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1030

Registration Number: NCT04100018

Locations: 🇺🇸
Local Institution - 0011, San Antonio, Texas, United States
🇺🇸
Local Institution - 0081, Santa Monica, California, United States
🇺🇸
Local Institution - 0055, Rancho Mirage, California, United States

and more 290 locations

Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma

Phase 3

Active, not recruiting

Conditions: Melanoma

Interventions: Other: Placebo
Biological: Nivolumab

First Posted Date: 2019-09-23

Last Posted Date: 2023-11-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 790

Registration Number: NCT04099251

Locations: 🇺🇸
Local Institution - 0135, Baltimore, Maryland, United States
🇺🇸
Local Institution - 0078, Boston, Massachusetts, United States
🇨🇦
Local Institution - 0124, Kingston, Ontario, Canada

and more 126 locations

A Study of Dasatinib Management Among CP-CML (Chronic Phase, Chronic Myeloid Leukemia) Participants Initiating Dasatinib in a Real Life Setting

Completed

Conditions: Chronic Myeloid Leukemia

Interventions: Other: Non-Interventional

First Posted Date: 2019-09-13

Last Posted Date: 2022-06-21

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 177

Registration Number: NCT04089839

Locations: 🇫🇷
Local Institution, Paris, France

An Investigational Study to Determine the Drug Level Profile of BMS-986165 in Healthy Male Volunteers Following Transporter Inhibition.

Phase 1

Completed

Conditions: Healthy Male Volunteers

Interventions: Drug: BMS-986165
Drug: Pyrimethamine

First Posted Date: 2019-09-12

Last Posted Date: 2020-08-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 16

Registration Number: NCT04086719

Locations: 🇺🇸
PRA Health Sciences - Salt Lake, Salt Lake City, Utah, United States

A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma

Phase 2

Terminated

Conditions: Renal Cell Carcinoma

Interventions: Biological: Nivolumab
Biological: Ipilimumab

First Posted Date: 2019-09-12

Last Posted Date: 2023-01-10

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 5

Registration Number: NCT04088500

Locations: 🇺🇸
Washington University School of Medicine in St. Louis WUSTL, Saint Louis, Missouri, United States
🇨🇦
Local Institution, Quebec City, Quebec, Canada
🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada

and more 6 locations

A Single and Multiple Ascending Dose Study of BMS-986318 in Healthy Participants

Phase 1

Withdrawn

Conditions: Healthy Participants

Interventions: Drug: BMS-986318
Other: Placebo

First Posted Date: 2019-09-09

Last Posted Date: 2020-01-27

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT04082741

Locations: 🇺🇸
PRA Health Sciences - Lenexa, Lenexa, Kansas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy